

HEMISPHERX BIOPHARMA INC
Form 8-K
June 06, 2016

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

June 6, 2016 (June 2, 2016)

HEMISPHERX BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware **0-27072** **52-0845822**
(state or other juris- (Commission (I.R.S. Employer
diction of incorporation) File Number) (Identification No.)

19103

**1617
JFK
Boulevard,
Suite
500,
Philadelphia,
PA**

(Address
of
principal
executive
offices)

Registrant's
telephone number,
including area code:
(215) 988-0080

**1617 JFK
Boulevard, Suite
500, Philadelphia,
PA 19103**

(Former name or
former address, if
changed since last
report)

Check the
appropriate box
below if the Form
8-K filing is
intended to
simultaneously
satisfy the filing
obligation of the
registrant under any
of the following
provisions (see
General Instruction
A.2. below):

Written
communications
..pursuant to Rule
425 under the
Securities Act (17
CFR 230.425)

..Soliciting material
pursuant to Rule
14a-12 under the
Exchange Act (17

CFR 240.14a-12)

Pre-commencement
communications
..pursuant to Rule
14d-2(b) under the
Exchange Act (17
CFR 240.14d-2(b))

Pre-commencement
communications
..pursuant to Rule
13e-4(c) under the
Exchange Act (17
CFR 240.13e-4(c))

Item 8.01. Other Events.

As noted in our Quarterly Report on Form 10-Q for the period ended March 31, 2016, the action against us commenced by William A. Carter in February 2016 in the United States District Court for the Southern District of Florida was settled. The Court dismissed with prejudice the filed litigation in accordance with the parties' agreed resolution, and retains jurisdiction to enforce the terms of the Parties' settlement agreement. On June 2, 2016, in furtherance of the settlement agreement, Dr. Carter executed an omnibus assignment to us of all of his Intellectual Property rights related to Ampligen® and Alferon®.

We issued a press release regarding the assignment of intellectual property on June 6, 2016. The press release is furnished herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1

Press Release dated June 6, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**HEMISPHERX
BIOPHARMA, INC.**

By: /s/ Thomas K. Equels
Thomas K. Equels
President

Date: June 6, 2016

